Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a class of drugs established for the treatment of type 2 diabetes and obesity. This review synthesizes current evidence that GLP-1RA exert anti-inflammatory effects in addition to their metabolic actions. The authors summarize findings from preclinical models and clinical studies across multiple disease domains and discuss potential translational applications as well as outstanding questions about mechanisms and causality. The review is published in the Journal of Clinical Endocrinology & Metabolism (2026) and is indexed with PMID 42219869 and DOI 10.1210/clinem/dgag218.
GLP-1RA have redefined care for people with type 2 diabetes and for weight management by producing reproducible benefits on glycemic control and body weight. Importantly, large clinical programs have demonstrated improved cardiovascular outcomes with agents in this class, which has driven interest in mechanisms beyond glucose lowering. The review positions these established metabolic and cardioprotective effects as a backdrop to exploring direct immunomodulatory actions of GLP-1RA.
The review reports accumulating preclinical data indicating that GLP-1RA can reduce inflammatory responses in multiple organ systems. Studies in animal models have examined effects on immune cell activation, cytokine profiles, and tissue inflammation in contexts relevant to cardiometabolic disease, neurodegeneration, inflammatory bowel disease, and sepsis. While the abstract highlights broad anti-inflammatory signals across models, specific experimental details, quantitative outcomes, and model-by-model findings are provided in the full text rather than in the abstract summary.
Clinical trial and human observational data add to preclinical signals, with some trials reporting markers of reduced inflammation alongside metabolic improvements. The review summarizes evidence from diverse clinical settings—cardiovascular disease, autoimmune disorders, neurodegeneration, and gastrointestinal inflammatory disease—indicating potential anti-inflammatory or immunomodulatory effects. The abstract does not enumerate individual trials or present pooled meta-analyses; those specifics reside in the full article.
By acting on both metabolic and inflammatory pathways, GLP-1RA may provide dual cardiometabolic and immunomodulatory protection. The review highlights the conceptual potential to repurpose or extend GLP-1RA use into nonmetabolic inflammatory diseases, including autoimmune conditions, neurodegenerative disorders, inflammatory bowel disease, and infectious or critical illness contexts such as sepsis. These proposed broader applications rest on translating preclinical and trial-phase biomarker changes into meaningful clinical outcomes.
The authors emphasize several unresolved issues:
Causality: It remains uncertain to what extent observed anti-inflammatory effects are independent of metabolic improvements (for example, weight loss or glycemic control) versus directly mediated by GLP-1 receptor signaling.
Molecular mechanisms: Precise pathways and cellular targets responsible for immunomodulation by GLP-1RA are incompletely defined in current literature.
Translational relevance: The extent to which preclinical anti-inflammatory signals and biomarker changes in trials predict clinically meaningful benefits in nonmetabolic inflammatory diseases is unclear.
Clinical trial design: Determining optimal populations, endpoints, and duration for trials that explicitly test anti-inflammatory or immunomodulatory outcomes will be important to establish therapeutic value outside cardiometabolic indications.
The review frames these gaps as priorities for future research and clinical investigation.
The review concludes that GLP-1RA show promising anti-inflammatory effects across preclinical models and human studies, supporting a hypothesis that these agents could confer immunomodulatory benefits in addition to metabolic and cardiovascular protection. However, the authors caution that key questions about causality, underlying molecular mechanisms, and the real-world translation of these effects into therapies for nonmetabolic inflammatory diseases remain unanswered. For full methodological details, trial descriptions, and comprehensive evidence tables, readers should consult the full article in J Clin Endocrinol Metab (2026). The review is authored by Luis Quintana, Nadim Tabaza, Berkan Kurt, and Florian Kahles, affiliated with the Department of Internal Medicine I–Cardiology, University Hospital Aachen, RWTH Aachen University. PMID 42219869; DOI 10.1210/clinem/dgag218.